Table 3 Genomic alterations before and after chemotherapy in the chemotherapy subgroups of Group B and Group C.
Patients no. | Sex | Regimens | The duration of therapy (m)/response | Before chemotherapy | After chemotherapy | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
KRAS | NRAS | BRAF | Site/(S/B/C) | KRAS | NRAS | BRAF | Site/(S/B/C) | ||||
B10 | F | FOLFIRI | 2.2/SD | WT | WT | WT | Colon/C | WT | WT | WT | Colon/S |
B11 | M | XELOX | 2.4/SD | WT | – | – | Colon/C | WT | – | – | Colon/S |
B12 | M | FOLFOX + BEV | 2.7/SD | WT | WT | WT | Colon/C | WT | WT | WT | Colon/S |
B13 | F | FOLFOX | 2.7/PR | WT | WT | WT | Colon/C | WT | WT | WT | Colon/S |
B14 | M | XELOX | 3.2/PR | WT | – | MT | Colon/C | WT | – | MT | Colon/S |
B15 | M | FOLFOX | 3.3/SD | WT | WT | WT | Colon/C | WT | WT | WT | Colon/S |
B16 | M | XELOX | 6.3/PR | WT | WT | WT | Colon/C | WT | WT | WT | Colon/S |
C17 | M | FOLFOX | 1.8/PD | WT | – | – | Colon/C | WT | – | – | Liver/B |
C18 | M | FOLFOX | 3.2/PD | WT | – | – | Colon/S | WT | – | – | Liver/B |
C19 | M | FOLFIRI | 4.9/SD | WT | – | – | Rectum/S | WT | – | – | Liver/S |
C20 | M | FOLFIRI | 26.8/PR | WT | – | – | Colon/C | WT | – | – | Colon/S |
C21 | M | CT | 50.1/CR | WT | WT | WT | Rectum/S | WT | WT | WT | Lymph node/B |
